Pilot pharmacokinetic and dosimetric studies of18F-FPPRGD2: A PET radiopharmaceutical agent for imaging αvβ3 integrin levels

Radiology

Volumn 260, Issue 1, 2011, Pages 182-191

  Mittra, Erik S ^a   Goris, Michael L ^a   Iagaru, Andrei H ^a   Kardan, Arash ^a   Burton, Lindee ^a   Berganos, Rhona ^a   Chang, Edwin ^a   Liu, Shuanglong ^a   Shen, Bin ^a   Chin, Frederick T ^a   Chen, Xiaoyuan ^c   Gambhir, Sanjiv S ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

^c NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 FLUOROPROPIONYL PEGYLATED ARGINYLGLYCYLASPARTIC ACID F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ADULT; AMINO ACID SEQUENCE; ARTICLE; BLOOD EXAMINATION; BLOOD SAMPLING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DOSIMETRY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERANCE; ELECTROCARDIOGRAM; FEMALE; HUMAN; HUMAN EXPERIMENT; IMAGE ANALYSIS; KIDNEY CLEARANCE; LIVER FUNCTION TEST; LOW DRUG DOSE; MALE; MICTURITION; NORMAL HUMAN; PILOT STUDY; PRIORITY JOURNAL; PROTEIN TARGETING; RADIATION DOSE; RADIOACTIVITY; SPLEEN FUNCTION; VITAL SIGN;

ADULT; BODY BURDEN; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; INTEGRIN ALPHAVBETA3; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; OLIGOPEPTIDES; ORGAN SPECIFICITY; PILOT PROJECTS; POSITRON-EMISSION TOMOGRAPHY; RADIATION DOSAGE; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION; WHOLE-BODY COUNTING;

EID: 79959567221     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.11101139     Document Type: Article

References (38)

1. Folkman J. Angiogenesis and angiogenesis inhibition: an overview. EXS 1997;79:1-8.
2. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002;29(6 Suppl 16):15-18.
3. Siemann DW, Chaplin DJ, Horsman MR. Vascular-targeting therapies for treatment of malignant disease. Cancer 2004;100(12):2491-2499. (Pubitemid 38715753)
4. Bhujwalla ZM, Artemov D, Natarajan K, Solaiyappan M, Kollars P, Kristjansen PE. Reduction of vascular and permeable regions in solid tumors detected by macromolecular contrast magnetic resonance imaging after treatment with antiangiogenic agent TNP-470. Clin Cancer Res 2003;9(1):355-362. (Pubitemid 36109752)
5. Eliceiri BP, Cheresh DA. Role of alpha v integrins during angiogenesis. Cancer J 2000;6(Suppl 3):S245-S249.
6. Felding-Habermann B, O'Toole TE, Smith JW, et al. Integrin activation controls metastasis in human breast cancer. Proc Natl Acad Sci U S A 2001;98(4):1853-1858. (Pubitemid 32165587)
7. Kerr JS, Slee AM, Mousa SA. The alpha v integrin antagonists as novel anticancer agents: an update. Expert Opin Investig Drugs 2002;11(12):1765-1774. (Pubitemid 35476838)
8. Haubner R, Wester HJ. Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies. Curr Pharm Des 2004;10(13):1439-1455. (Pubitemid 38559759)
9. Willmann JK, Cheng Z, Davis C, et al. Targeted microbubbles for imaging tumor angiogenesis: assessment of whole-body biodistribution with dynamic micro-PET in mice. Radiology 2008;249(1):212-219.
10. Willmann JK, Kimura RH, Deshpande N, Lutz AM, Cochran JR, Gambhir SS. Targeted contrast-enhanced ultrasound imaging of tumor angiogenesis with contrast microbubbles conjugated to integrin-binding knottin peptides. J Nucl Med 2010;51(3):433-440.
11. Willmann JK, Lutz AM, Paulmurugan R, et al. Dual-targeted contrast agent for US assessment of tumor angiogenesis in vivo. Radiology 2008;248(3):936-944.
12. Willmann JK, Paulmurugan R, Chen K, et al. US imaging of tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice. Radiology 2008;246(2):508-518.
13. Sipkins DA, Cheresh DA, Kazemi MR, Nevin LM, Bednarski MD, Li KC. Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Nat Med 1998;4(5):623-626. (Pubitemid 28237365)
14. Chen X, Conti PS, Moats RA. In vivo near-infrared fluorescence imaging of integrin alphavbeta3 in brain tumor xenografts. Cancer Res 2004;64(21):8009- 8014.
15. Wang W, Ke S, Wu Q, et al. Near-infrared optical imaging of integrin alphavbeta3 in human tumor xenografts. Mol Imaging 2004;3(4):343-351. (Pubitemid 40245456)
16. Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2002;2(9):683-693. (Pubitemid 37328919)
17. Haubner R, Kuhnast B, Mang C, et al. [18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjug Chem 2004;15(1):61-69.
18. Haubner R, Wester HJ, Weber WA, et al. Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 2001;61(5):1781-1785.
19. Haubner R, Weber WA, Beer AJ, et al. Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F] Galacto-RGD. PLoS Med 2005;2(3):e70.
20. Chen X, Hou Y, Tohme M, et al. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression. J Nucl Med 2004;45(10):1776-1783. (Pubitemid 47618490)
21. Chen X, Park R, Hou Y, et al. MicroPET imaging of brain tumor angiogenesis with 18F-labeled PEGylated RGD peptide. Eur J Nucl Med Mol Imaging 2004;31(8):1081-1089. (Pubitemid 39050174)
22. Vagner J, Handl HL, Gillies RJ, Hruby VJ. Novel targeting strategy based on multimeric ligands for drug delivery and molecular imaging: homooligomers of alpha-MSH. Bioorg Med Chem Lett 2004;14(1):211-215. (Pubitemid 38010222)
23. Rao J, Lahiri J, Isaacs L, Weis RM, Whitesides GM. A trivalent system from vancomycin. D-ala-D-Ala with higher affinity than avidin. biotin. Science 1998;280(5364):708-711.
24. Li ZB, Chen K, Chen X. (68)Ga-labeled multi-meric RGD peptides for microPET imaging of integrin alpha(v)beta (3) expression. Eur J Nucl Med Mol Imaging 2008;35(6):1100-1108.
25. Li ZB, Wu Z, Chen K, Chin FT, Chen X. Click chemistry for (18)F-labeling of RGD peptides and microPET imaging of tumor integrin alphavbeta3 expression. Bioconjug Chem 2007;18(6):1987-1994.
26. Wu Z, Li ZB, Chen K, et al. MicroPET of tumor integrin alphavbeta3 expression using 18F-labeled PEGylated tetrameric RGD peptide (18F-FPRGD4). J Nucl Med 2007;48(9):1536-1544. (Pubitemid 47397404)
27. Li ZB, Cai W, Cao Q, et al. (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression. J Nucl Med 2007;48(7):1162-1171.
28. Wu Z, Li ZB, Cai W, et al. 18F-labeled mini-PEG spacered RGD dimer (18F-FPRGD2): synthesis and microPET imaging of alphavbeta3 integrin expression. Eur J Nucl Med Mol Imaging 2007;34(11):1823-1831. (Pubitemid 47599045)
29. Liu S, Liu Z, Chen K, et al. 18F-labeled galacto and PEGylated RGD dimers for PET imaging of a v b 3 integrin expression. Mol Imaging Biol 2010;12(5):530-538.
30. Chin FT, Shen B, Liu S, et al. Initial experience with clinical-grade [18F]FPP(RGD)2: an automated multi-step radiosynthesis for clinical PET studies. J Nucl Med(in press ).
31. 2: an automated multi-step radiosynthesis for clinical PET studies. Mol Imaging Biol (in press).
32. Stabin MG, Sparks RB, Crowe E. OLINDA/ EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 2005;46(6):1023-1027. (Pubitemid 43733519)
33. International Commission on Radiological Protection. Radiation protection in medicine. ICRP publication 105. Ann ICRP 2007;37(6):1-63.
34. International Commission on Radiological Protection. The 2007 recommendations of the International Commission on Radiological Protection. ICRP publication 103. Ann ICRP 2007;37(2-4):1-332.
35. Beer AJ, Schwaiger M. Imaging of integrin alphavbeta3 expression. Cancer Metastasis Rev 2008;27(4):631-644.
36. Leide-Svegborn S. Radiation exposure of patients and personnel from a PET/CT procedure with 18F-FDG. Radiat Prot Dosimetry 2010;139(1-3):208-213.
37. McParland BJ, Miller MP, Spinks TJ, et al. The biodistribution and radiation dosimetry of the Arg-Gly-Asp peptide 18F-AH111585 in healthy volunteers. J Nucl Med 2008;49(10):1664-1667.
38. Higuchi T, Bengel FM, Seidl S, et al. Assessment of alphavbeta3 integrin expression after myocardial infarction by positron emission tomography. Cardiovasc Res 2008;78(2):395-403. (Pubitemid 351556104)